NASDAQ:CRIS - Curis Stock Price, Price Target & More

$0.59 -0.01 (-1.67 %)

(As of 04/19/2018 11:30 AM ET)

Previous Close$0.60

Today's Range$0.58 - $0.61

52-Week Range$0.47 - $2.70

Volume290,444 shs

Average Volume2.10 million shs

Market Capitalization$103.47 million

P/E Ratio-1.67

Dividend YieldN/A

Beta1.29

About Curis (NASDAQ:CRIS)

Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:CRIS

CUSIP23126910

Webwww.curis.com

Phone617-503-6500

Debt

Debt-to-Equity Ratio1.49%

Current Ratio4.56%

Quick Ratio4.56%

Price-To-Earnings

Trailing P/E Ratio-1.67

Forward P/E Ratio-1.55

P/E GrowthN/A

Sales & Book Value

Annual Sales$9.90 million

Price / Sales9.87

Cash FlowN/A

Price / CashN/A

Book Value$0.15 per share

Price / Book3.93

Profitability

EPS (Most Recent Fiscal Year)($0.36)

Net Income$-53,310,000.00

Net Margins-538.66%

Return on Equity-250.55%

Return on Assets-72.61%

Miscellaneous

Employees55

Outstanding Shares165,630,000

How to Become a New Pot Stock Millionaire

Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) announced its earnings results on Thursday, March, 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.04. The biotechnology company earned $3.26 million during the quarter, compared to the consensus estimate of $2.03 million. Curis had a negative return on equity of 250.55% and a negative net margin of 538.66%. During the same period last year, the firm earned ($0.08) earnings per share. View Curis' Earnings History.

When is Curis' next earnings date?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Curis.

What price target have analysts set for CRIS?

2 Wall Street analysts have issued 1 year price targets for Curis' shares. Their predictions range from $7.00 to $7.00. On average, they anticipate Curis' share price to reach $7.00 in the next year. View Analyst Ratings for Curis.

What are Wall Street analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:

1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (2/8/2018)
2. Cowen Inc analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Some companies that are related to Curis include Pluristem Therapeutics (PSTI), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Lorus Therapeutics (APTO), Applied Genetic Technologies (AGTC), Medgenics (GNMX), Cidara Therapeutics (CDTX), Genocea Biosciences (GNCA), aTyr Pharma (LIFE), Brainstorm Cell Therapeutics (BCLI), CytRx (CYTR), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), Vaxart (VXRT), Vical (VICL), Microbot Medical (MBOT), Neuralstem (CUR) and Oncobiologics (ONS).

Who are Curis' key executives?

Curis' management team includes the folowing people:

Dr. Ali Fattaey, CEO, Pres & Director (Age 53)
Mr. James E. Dentzer, CFO, Chief Admin. Officer & Principal Accounting Officer (Age 51)
Dr. David Tuck, Sr. VP & Chief Medical Officer (Age 66)
Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 57)
Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 59)

Has Curis been receiving favorable news coverage?

News headlines about CRIS stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Curis earned a daily sentiment score of 0.22 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $0.59.

How big of a company is Curis?

Curis has a market capitalization of $103.47 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Curis employs 55 workers across the globe.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]

MarketBeat Community Rating for Curis (CRIS)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		327 (Vote Outperform)
Underperform Votes:		252 (Vote Underperform)
Total Votes:		579

MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Curis (NASDAQ:CRIS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Curis in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 1,086.44%. The high price target for CRIS is $7.00 and the low price target for CRIS is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.00	$7.00	$6.50	$6.00
Price Target Upside:	1,086.44% upside	345.86% upside	314.01% upside	214.14% upside

Curis (NASDAQ:CRIS) Consensus Price Target History

Price Target History for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/23/2017	Guggenheim	Initiated Coverage	Buy	$7.00	N/A
5/15/2017	Cowen	Reiterated Rating	Buy		N/A
3/11/2017	FBR & Co	Set Price Target	Buy	$6.00	Low
10/12/2016	Royal Bank of Canada	Set Price Target	Buy	$7.00	N/A
9/7/2016	Robert W. Baird	Reiterated Rating	Outperform	$7.00	N/A

(Data available from 4/19/2016 forward)

Curis (NASDAQ:CRIS) Earnings History and Estimates Chart

Earnings by Quarter for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.31)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.07)	($0.07)	($0.07)
Q2 2018	1	($0.08)	($0.08)	($0.08)
Q3 2018	1	($0.08)	($0.08)	($0.08)
Q4 2018	1	($0.08)	($0.08)	($0.08)

Curis (NASDAQ CRIS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		($0.09)					N/A
3/8/2018	Q4 2017	($0.09)	($0.05)	$2.03 million	$3.26 million	View	Listen
11/7/2017	Q3 2017	($0.09)	($0.11)	$2.19 million	$2.44 million	View	N/A
8/3/2017	Q2 2017	($0.0930)	($0.10)	$2.08 million	$2.10 million	View	Listen
5/4/2017	Q1 17	($0.0870)	($0.11)	$1.98 million	$2.13 million	View	Listen
3/9/2017	Q4 2016	($0.10)	($0.08)	$1.97 million	$2.40 million	View	Listen
11/3/2016	Q316	($0.10)	($0.21)	$1.84 million	$1.80 million	View	Listen
8/4/2016	Q216	($0.09)	($0.09)	$2.05 million	$1.70 million	View	Listen
5/9/2016	Q116	($0.08)	($0.07)	$2.30 million	$1.70 million	View	Listen
2/29/2016	Q415	($0.12)	($0.10)	$2.98 million	$2.10 million	View	Listen
11/9/2015	Q315	($0.08)	($0.04)	$2.82 million	$2.00 million	View	N/A
8/6/2015	Q215	($0.06)	($0.06)	$3.50 million	$2.10 million	View	N/A
5/7/2015	Q115	($0.06)	($0.07)	$2.27 million	$1.17 million	View	N/A
2/24/2015	Q4 14	($0.07)	($0.07)	$2.69 million	$2.00 million	View	N/A
11/10/2014	Q314	($0.05)	($0.06)	$4.13 million	$1.80 million	View	N/A
8/7/2014	Q214	($0.06)	($0.02)	$3.46 million	$4.80 million	View	N/A
5/8/2014	Q114	($0.07)	($0.06)	$1.88 million	$1.30 million	View	N/A
2/20/2014	Q413	($0.08)	($0.05)	$1.59 million	$1.52 million	View	N/A
11/5/2013	Q313	($0.01)	($0.02)	$6.44 million	$7.20 million	View	N/A
8/5/2013	Q2 2013	($0.05)	($0.02)	$4.43 million	$5.40 million	View	N/A
4/30/2013	Q1 2013	($0.05)	($0.06)	$3.86 million	$0.90 million	View	N/A
2/20/2013	Q4 2012	($0.08)	($0.15)	$2.07 million	$1.69 million	View	N/A
11/6/2012	Q312	($0.08)	($0.04)	$1.01 million	$0.60 million	View	N/A
8/2/2012		($0.05)	($0.04)			View	N/A
5/8/2012		$0.02	$0.03			View	N/A
2/8/2012	Q4 2011	$0.06	$0.08			View	N/A
10/27/2011		($0.07)	($0.05)			View	N/A
7/28/2011		($0.07)	($0.06)			View	N/A
4/28/2011	Q1 2011	($0.07)	($0.09)			View	N/A
2/10/2011	Q4 2010	($0.06)	($0.07)			View	N/A
10/28/2010	Q3 2010	($0.03)	($0.02)			View	N/A
8/3/2010	Q2 2010	($0.04)	($0.03)			View	N/A
5/6/2010	Q1 2010	$0.05	$0.06			View	N/A
2/25/2010	Q4 2009	($0.05)	($0.04)			View	N/A
10/29/2009	Q3 2009	($0.06)	($0.06)			View	N/A
7/30/2009	Q2 2009	($0.07)	($0.07)			View	N/A
5/5/2009	Q1 2009	$0.01	$0.02			View	N/A
2/10/2009	Q4 2008	($0.03)	($0.03)			View	N/A
10/28/2008	Q3 2008		($0.07)			View	N/A
7/30/2008	Q2 2008		($0.03)			View	N/A
4/30/2008	Q1 2008		($0.05)			View	N/A
2/14/2008	Q4 2007		$0.07			View	N/A

(Earnings results data provided by Zacks Investment Research)

Curis (NASDAQ:CRIS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Curis (NASDAQ CRIS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.34%
Institutional Ownership Percentage: 47.66%

Insider Trading History for Curis (NASDAQ:CRIS)

Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Curis (NASDAQ CRIS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/16/2017	Marc Rubin	Director	Buy	25,000	$0.98	$24,500.00	51,596
11/15/2017	Ali Ph.D. Fattaey	CEO	Buy	50,000	$1.06	$53,000.00	115,890
5/5/2017	James R Mcnab	Director	Sell	76,276	$2.04	$155,603.04	879,688
5/2/2017	James R Mcnab	Director	Sell	116,708	$2.38	$277,765.04
4/27/2017	James R Mcnab	Director	Sell	146,694	$2.61	$382,871.34	912,426
4/24/2017	James R Mcnab	Director	Sell	110,322	$2.59	$285,733.98	1,357,147
9/7/2016	Discovery Technologie Aurigene	Major Shareholder	Buy	10,208,333	$2.40	$24,499,999.20	27,328,464
5/27/2016	Martyn D Greenacre	Director	Sell	15,000	$1.69	$25,350.00	40,183
5/26/2016	Kenneth I Kaitin	Director	Sell	15,000	$1.76	$26,400.00	31,800
12/30/2015	Daniel R. Passeri	Director	Sell	14,400	$3.01	$43,344.00	198,898
12/29/2015	Daniel R. Passeri	Director	Sell	11,200	$2.91	$32,592.00	198,898
12/28/2015	Daniel R. Passeri	Director	Sell	13,600	$2.85	$38,760.00	198,898
12/23/2015	Daniel R. Passeri	Director	Sell	48,900	$2.78	$135,942.00	198,898
12/21/2015	Daniel R. Passeri	Director	Sell	289,000	$2.99	$864,110.00	198,898
8/27/2014	Ali Ph.D. Fattaey	CEO	Buy	62,890	$1.60	$100,624.00
12/11/2013	Ali Ph.D. Fattaey	COO	Buy	3,000	$2.52	$7,560.00	3,000
11/12/2013	Michael Gray	CFO	Buy	10,000	$2.86	$28,600.00	107,304
11/8/2013	Kenneth Pienta	Director	Buy	20,000	$2.95	$59,000.00	30,000
8/16/2013	James Mcnab	Director	Sell	50,000	$4.00	$200,000.00	1,079,688
12/6/2012	Daniel R Passeri	CEO	Buy	25,000	$3.03	$75,750.00

(Data available from 1/1/2013 forward)

Curis (NASDAQ CRIS) News Headlines

Source:

Date	Headline
	Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10% finance.yahoo.com - April 19 at 8:22 AM
	Curis (CRIS) Downgraded to Sell at BidaskClub www.americanbankingnews.com - April 15 at 1:49 PM
	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) www.prnewswire.com - April 6 at 7:33 AM
	Zacks: Analysts Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.30 Million www.americanbankingnews.com - April 5 at 4:20 AM
	-$0.08 EPS Expected for Curis, Inc. (CRIS) This Quarter www.americanbankingnews.com - April 3 at 9:18 AM
	Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of Influence finance.yahoo.com - April 3 at 8:30 AM
	Curis (CRIS) & Vical (VICL) Financial Comparison www.americanbankingnews.com - April 2 at 5:22 AM
	Curis (CRIS) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 29 at 8:30 PM
	BRIEF-Curis Inc Says James Dentzer Became COO And CFO Of Co www.reuters.com - March 22 at 5:31 PM
	Curis: Time To Bet On A Courageous Choice seekingalpha.com - March 20 at 5:12 PM
	Brokerages Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.30 Million www.americanbankingnews.com - March 19 at 7:56 AM
	Head-To-Head Contrast: Kura Oncology (KURA) & Curis (CRIS) www.americanbankingnews.com - March 17 at 8:07 AM
	Curis, Inc. (CRIS) Expected to Announce Earnings of -$0.08 Per Share www.americanbankingnews.com - March 17 at 5:18 AM
	Curis (CRIS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow seekingalpha.com - March 15 at 6:03 PM
	What Are Analysts Saying About Curis Inc’s (NASDAQ:CRIS) Earnings Trend? finance.yahoo.com - March 15 at 6:03 PM
	Curis (CRIS) Announces Earnings Results, Beats Estimates By $0.04 EPS www.americanbankingnews.com - March 9 at 10:35 AM
	Curis Reports Fourth Quarter and Year-End 2017 Financial Results finance.yahoo.com - March 8 at 6:31 PM
	Curis Reports Fourth Quarter and Year-End 2017 Financial Results - PR Newswire (press release) www.prnewswire.com - March 8 at 8:30 AM
	Curis to Present at Cowen & Company 38th Annual Health Care Conference - PR Newswire (press release) www.prnewswire.com - March 5 at 8:28 AM
	Curis to Present at Cowen & Company 38th Annual Health Care Conference finance.yahoo.com - March 5 at 8:27 AM
	Curis, Inc. (CRIS) Sees Significant Growth in Short Interest www.americanbankingnews.com - March 3 at 3:26 AM
	Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million www.americanbankingnews.com - March 2 at 2:24 PM
	Baird Financial Group Inc. Decreases Stake in Curis, Inc. (CRIS) www.americanbankingnews.com - March 2 at 4:42 AM
	Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018 - PR Newswire (press release) www.prnewswire.com - March 1 at 8:20 AM
	Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018 finance.yahoo.com - March 1 at 8:20 AM
	Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - February 28 at 3:32 AM
	Zacks: Brokerages Anticipate Curis, Inc. (CRIS) Will Post Earnings of -$0.09 Per Share www.americanbankingnews.com - February 28 at 3:12 AM
	Curis (CRIS) to Release Earnings on Wednesday www.americanbankingnews.com - February 28 at 1:40 AM
	Brokers Offer Predictions for Curis, Inc.'s FY2022 Earnings (CRIS) www.americanbankingnews.com - February 22 at 4:34 PM
	Curis (CRIS) Upgraded at Zacks Investment Research www.americanbankingnews.com - February 11 at 5:12 PM
	Capstone Turbine Corporation (CPST) and Seadrill Ltd (SDRL) Among Hedge Funds’ Favorite Penny Stocks finance.yahoo.com - February 8 at 8:15 AM
	Curis, Inc. (CRIS) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - February 3 at 3:26 AM
	Short Interest in Curis, Inc. (CRIS) Expands By 101.8% www.americanbankingnews.com - January 28 at 1:26 AM
	Curis, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share www.americanbankingnews.com - January 25 at 1:29 PM
	Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 - StreetInsider.com www.streetinsider.com - January 18 at 10:46 AM
	Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 www.streetinsider.com - January 17 at 9:45 AM
	Curis Begins Phase 1 Trial Of CA-4948 In Patients With Lymphomas - Quick Facts www.nasdaq.com - January 17 at 9:45 AM
	Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma finance.yahoo.com - January 17 at 9:45 AM
	Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 Million www.americanbankingnews.com - January 10 at 5:00 PM
	Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 Earnings Per Share www.americanbankingnews.com - January 8 at 9:36 AM
	Curis, Inc. (CRIS) Expected to Post Quarterly Sales of $2.03 Million www.americanbankingnews.com - December 25 at 10:32 PM
	ETFs with exposure to Curis, Inc. : December 25, 2017 finance.yahoo.com - December 25 at 6:42 PM
	Want To Invest In Curis Inc (NASDAQ:CRIS)? Here’s How It Performed Lately finance.yahoo.com - December 21 at 5:01 PM
	Curis (CRIS) vs. Cellular Dynamics International (ICEL) Financial Survey www.americanbankingnews.com - December 16 at 5:16 AM
	Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - December 15 at 3:32 AM
	ETFs with exposure to Curis, Inc. : December 12, 2017 finance.yahoo.com - December 12 at 5:24 PM
	-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter www.americanbankingnews.com - December 5 at 7:12 AM
	Curis (CRIS) Announces Upcoming Presentation at ASH - StreetInsider.com www.streetinsider.com - December 1 at 5:11 PM
	Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition finance.yahoo.com - December 1 at 5:11 PM
	ETFs with exposure to Curis, Inc. : November 30, 2017 finance.yahoo.com - November 30 at 4:58 PM

Curis (NASDAQ:CRIS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Curis (NASDAQ:CRIS) Income Statement, Balance Sheet and Cash Flow Statement

Curis (NASDAQ CRIS) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff